DexCom, Inc.’s Stelo continuous glucose monitor (CGM) became available in the US on 26 August for diabetics, prediabetics and healthy consumers alike, making it the first such product sold in the country that does not require a prescription.
Dexcom’s Stelo Continuous Glucose Monitor Now Available OTC In US
Dexcom announced the launch of Stelo, the first non-prescription continuous glucose monitoring system to hit the US market, but is likely going to face competition soon from Abbott.
More from Business
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
More from Beauty
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.
• By
Cosmetic companies should conduct audits to identify products that will be required to disclose fragrance allergens and begin the work of adjusting labels, particularly for smaller packaging, says a director at Registrar Corp., during a 12 March webinar on MoCRA and labeling.